Sentman CL - Search Results

1

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Baumeister SH, et al. Among authors: sentman cl. Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5. Cancer Immunol Res. 2019. PMID: 30396908 Free PMC article. Clinical Trial.

2

Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.

Zhang T, Barber A, Sentman CL. Zhang T, et al. Among authors: sentman cl. Cancer Res. 2006 Jun 1;66(11):5927-33. doi: 10.1158/0008-5472.CAN-06-0130. Cancer Res. 2006. PMID: 16740733

3

NK cell receptors as tools in cancer immunotherapy.

Sentman CL, Barber MA, Barber A, Zhang T. Sentman CL, et al. Adv Cancer Res. 2006;95:249-92. doi: 10.1016/S0065-230X(06)95007-6. Adv Cancer Res. 2006. PMID: 16860660 Review.

4

Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.

Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Barber A, et al. Among authors: sentman cl. Cancer Res. 2007 May 15;67(10):5003-8. doi: 10.1158/0008-5472.CAN-06-4047. Cancer Res. 2007. PMID: 17510432

5

Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.

Zhang T, Barber A, Sentman CL. Zhang T, et al. Among authors: sentman cl. Cancer Res. 2007 Nov 15;67(22):11029-36. doi: 10.1158/0008-5472.CAN-07-2251. Cancer Res. 2007. PMID: 18006849

6

Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

Barber A, Zhang T, Sentman CL. Barber A, et al. Among authors: sentman cl. J Immunol. 2008 Jan 1;180(1):72-8. doi: 10.4049/jimmunol.180.1.72. J Immunol. 2008. PMID: 18097006

7

Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.

Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Barber A, et al. Among authors: sentman cl. Exp Hematol. 2008 Oct;36(10):1318-28. doi: 10.1016/j.exphem.2008.04.010. Epub 2008 Jul 2. Exp Hematol. 2008. PMID: 18599182 Free PMC article.

8

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR. Huarte E, et al. Among authors: sentman cl. Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3. Cancer Res. 2008. PMID: 18768667 Free PMC article.

9

Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs.

Basu S, Eriksson M, Pioli PA, Conejo-Garcia J, Mselle TF, Yamamoto S, Wira CR, Sentman CL. Basu S, et al. Among authors: sentman cl. Am J Reprod Immunol. 2009 Jan;61(1):52-61. doi: 10.1111/j.1600-0897.2008.00661.x. Am J Reprod Immunol. 2009. PMID: 19086992 Free PMC article.

10

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Barber A, Sentman CL. Barber A, et al. Among authors: sentman cl. J Immunol. 2009 Aug 15;183(4):2365-72. doi: 10.4049/jimmunol.0900721. Epub 2009 Jul 22. J Immunol. 2009. PMID: 19625653 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters